1. General Information

Cohort ID	5020_21
Title (Study Name)	The CoVVacBoost Study
Principal investigator	Assoc. Prof. Martin Stradner, Prof. Ivo Steinmetz
Contact information	pm-biobank@medunigraz.at
Funding agency	----

2. Description

The aim of this study is to evaluate the ability of a COVID-19 booster vaccine to induce a salivary antibody response and to investigate a possible correlation with the serum antibody response and the cellular response. A quantitative and functional comparison of the salivary anti-SARS-CoV-2 antibody response before and after 3rd booster vaccination will be investigated. Volunteers, who get their 3rd vaccination at the "Impfstraße" at the LKH-Univ. Klinikum Graz are asked to participate in this study. Blood and saliva samples will be obtained during 3 visits.

Visit 1 (before the 3rd booster vaccination): Serology, PBMCs, saliva
Visit 2 (3 – 8 weeks after the 3rd booster vaccination): Serology, PBMCs, saliva
Visit 3: 6 months after the 3rd booster vaccination: Serology, saliva

The following data are collected for all participants: type of COVID-19 vaccinations, medical history (including immunosuppressive therapies, chronic graft versus host disease, severe opportunistic infections, prior vaccination history (types, titers if available), current and past disease including COVID-19), current medication, BMI, smoking habits.

3. Details

ICD 10/O codes / Healthy	healthy	
Key words	vaccination, COVID-19, SARS-CoV-2, mRNA vaccine, booster, 3rd dose, Moderna, Comirnaty, AstraZeneca	
Collection / Cohort size 12/2023	1.571 serum, 370 saliva and 553 PBMC aliquots from 140 patients	
Informed Consent (IC)	☒ Broad Biobank IC	
	☒ Specific Study IC	
Status	☒ In progress / compl. date: 01/2023	
	☐ Completed	
Inclusion criteria	**Age distribution**	18+
	Sex distribution (f:m)	~50:50
	Others	• second dose AstraZeneca plus third dosis Moderna • second dose AstraZeneca plus third dosis Comirnaty • second dose Moderna plus third dosis Moderna • second dose Comirnaty plus third dosis Comirnaty
Earliest access	As of now	

Quality-standards	☒ ISO 9001:2015 (SOPs)
Associated publications / references	-----

4. Material available (aliquot size) and storage conditions

Material	☒ Serum (580 µl)	☒ -80°C	☐ liq. N_2
	☒ PBMC´s	☒ -80°C	☒ liq. N_2
	☒ Saliva	☒ -80°C	☐ liq. N_2

Dokument erstellt (tt/mm/yyyy)**:** 22/12/2021	**Letzte inhaltliche Aktualisierung** (tt/mm/yyyy)**:** 21/03/2024